

NET ASSET VALUE 2024 06 30

On the 30 June 2024 Flerie AB's ("Flerie") Net Asset Value (NAV) was SEK 4,380 million and NAV per share was SEK 0.561.

Allocation of net asset value	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development				
Prokarium	42%	471	0.060	10.8%
Xspray Pharma	17%	461	0.059	10.5%
Empros Pharma	79%	204	0.026	4.7%
KAHR Medical	31%	200	0.026	4.6%
Atrogi	34%	154	0.020	3.5%
Microbiotica	11%	134	0.017	3.1%
Xintela	56%	105	0.013	2.4%
Mendus	24%	103	0.013	2.4%
Geneos Therapeutics	12%	102	0.013	2.3%
Lipum	57%	98	0.013	2.2%
Toleranzia	58%	76	0.010	1.7%
Synerkine Pharma	43%	52	0.007	1.2%
AnaCardio	19%	52	0.007	1.2%
Egetis Therapeutics	2%	34	0.004	0.8%
Buzzard Pharmaceuticals	14%	29	0.004	0.7%
Vitara Biomedical	5%	28	0.004	0.6%
Sixera Pharma	23%	26	0.003	0.6%
Alder Therapeutics	21%	17	0.002	0.4%
Amarna Therapeutics	60%	12	0.001	0.3%
Strike Pharma	14%	6	0.001	0.1%
EpiEndo Pharmaceuticals	10%	0	0.000	0.0%
Total		2,365	0.303	54.0%
Commercial Growth				
NorthX Biologics	92%	189	0.024	4.3%
Symcel	31%	169	0.022	3.9%
Nanologica	39%	95	0.012	2.2%
A3P Biomedical	8%	75	0.010	1.7%
Provell Pharmaceuticals	72%	67	0.009	1.5%
Chromafora	32%	53	0.007	1.2%
Frontier Biosolutions	2%	19	0.002	0.4%
Bohus Biotech	45%	17	0.002	0.4%
Total		683	0.088	15.6%
Limited Partnerships, total		76	0.010	1.7%

Assets related to portfolio companies		376	0.048	8.6%
Other assets and liabilities		879	0.113	20.1%
Net asset value		4.380	0.561	100.0%
<i>* indirect shares in Provell Pharmaceuticals</i>				

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[NET ASSET VALUE 2024 06 30](#)